Boehringer In­gel­heim touts pre­ven­tion re­sults in rarest form of pso­ri­a­sis

Boehringer In­gel­heim un­corked some pos­i­tive re­sults sug­gest­ing that Spe­vi­go can help pre­vent flare-ups in pa­tients with a se­vere form of pso­ri­a­sis, months af­ter the drug was ap­proved to treat ex­ist­ing flares.

Spe­vi­go, an IL-36R an­ti­body al­so known as spesolimab, met its pri­ma­ry and a key sec­ondary end­point in the Phase IIb EFF­ISAY­IL 2 tri­al in pa­tients with gen­er­al­ized pus­tu­lar pso­ri­a­sis (GPP), Boehringer an­nounced on Mon­day. While the com­pa­ny is keep­ing the hard num­bers un­der wraps un­til lat­er this year, it said in a news re­lease that it an­tic­i­pates shar­ing the re­sults with reg­u­la­tors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER